PE20170427A1 - Peptidos como agonistas de la oxitocina - Google Patents
Peptidos como agonistas de la oxitocinaInfo
- Publication number
- PE20170427A1 PE20170427A1 PE2016002273A PE2016002273A PE20170427A1 PE 20170427 A1 PE20170427 A1 PE 20170427A1 PE 2016002273 A PE2016002273 A PE 2016002273A PE 2016002273 A PE2016002273 A PE 2016002273A PE 20170427 A1 PE20170427 A1 PE 20170427A1
- Authority
- PE
- Peru
- Prior art keywords
- lower alkyl
- hydrogen
- peptides
- cycloalkyl
- compounds
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- 102400000050 Oxytocin Human genes 0.000 title 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 title 1
- 101800000989 Oxytocin Proteins 0.000 title 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title 1
- 229960001723 oxytocin Drugs 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102000004279 Oxytocin receptors Human genes 0.000 abstract 1
- 108090000876 Oxytocin receptors Proteins 0.000 abstract 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se refiere a compuestos de formula (I), donde: R1 es hidrogeno, alquilo inferior, -CH2-cicloalquilo o cicloalquilo; R2 es hidrogeno, alquilo inferior o alquilo inferior sustituido con hidroxi; o R1 y R2 pueden formar junto con el atomo de N y C al que estan unidos un anillo de pirrolidina opcionalmente sustituido, una azetidina o un anillo de piperidina; R3 es hidrogeno, alquilo inferior, entre otros; R3' es hidrogeno o alquilo inferior; n es 1; m es 0 o 1; o es 1 a 4. Tambien se refiere a una composicion farmaceutica. Dichos compuestos son agonistas del receptor de oxitocina, siendo utiles en el tratamiento del autismo, el estres, la ansiedad, incluyendo trastornos de ansiedad y la depresion, la esquizofrenia, entre otros
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14171440 | 2014-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170427A1 true PE20170427A1 (es) | 2017-04-26 |
Family
ID=50932985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016002273A PE20170427A1 (es) | 2014-06-06 | 2015-06-03 | Peptidos como agonistas de la oxitocina |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20170081368A1 (es) |
| EP (1) | EP3152225B1 (es) |
| JP (1) | JP6535688B2 (es) |
| KR (1) | KR20170004014A (es) |
| CN (1) | CN106459156A (es) |
| AU (1) | AU2015270564A1 (es) |
| CA (1) | CA2950493A1 (es) |
| CL (1) | CL2016003076A1 (es) |
| CR (1) | CR20160562A (es) |
| EA (1) | EA030296B1 (es) |
| IL (1) | IL248625A0 (es) |
| MX (1) | MX2016015877A (es) |
| PE (1) | PE20170427A1 (es) |
| PH (1) | PH12016502251A1 (es) |
| SG (1) | SG11201610221WA (es) |
| WO (1) | WO2015185584A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112773765A (zh) | 2014-09-19 | 2021-05-11 | 辉凌公司 | 治疗普拉德-威利综合征的方法 |
| WO2019032946A1 (en) | 2017-08-11 | 2019-02-14 | Ferring B.V. | PROCESS FOR PRODUCING OXYTOCIN |
| KR102704660B1 (ko) | 2017-08-11 | 2024-09-06 | 훼링 비.브이. | 약학적 조성물의 제조 방법 |
| US11207373B2 (en) | 2018-09-20 | 2021-12-28 | Levo Therapeutics, Inc. | Agitation process for preparing a carbetocin drug product |
| TW202031283A (zh) | 2018-09-20 | 2020-09-01 | 馬克 Ｃ 曼寧 | 穩定卡貝縮宮素鼻內製劑 |
| CN113801200B (zh) * | 2021-09-28 | 2023-07-25 | 浙江湃肽生物有限公司 | 一种卡贝缩宫素的制备方法 |
| WO2024044633A2 (en) * | 2022-08-23 | 2024-02-29 | Seattle Children's Hospital (D/B/A Seattle Children's Research Institute) | Oxytocin derivatives and methods of use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4483794A (en) * | 1983-05-10 | 1984-11-20 | Ceskoslovenska Akademie Ved | Analogs of neurohypophysial hormones |
| KR20070022753A (ko) * | 2004-05-26 | 2007-02-27 | 화이자 인코포레이티드 | 인다졸 및 인돌론 유도체 및 이의 약제로서의 용도 |
| FR2875499B1 (fr) * | 2004-09-20 | 2006-10-27 | Sanofi Aventis Sa | Nouveaux derives pyridiniques d'indolin-2-one, leur preparation et leur application en therapeutique |
| KR101763674B1 (ko) * | 2007-01-22 | 2017-08-01 | 지티엑스, 인코포레이티드 | 핵 수용체에 결합하는 물질 |
| NZ587817A (en) * | 2008-03-31 | 2012-05-25 | Ferring Bv | Oxytocin analogues |
| JP2012502948A (ja) * | 2008-09-23 | 2012-02-02 | エフ．ホフマン−ラ ロシュ アーゲー | ドーパミンｄ３受容体の調節剤として有用なイソオキサゾロ［４，５］ピリジン−３−イル−ピペラジン誘導体 |
| US8410104B2 (en) * | 2009-05-05 | 2013-04-02 | Hoffmann-La Roche Inc. | Pyridazines |
| TWI463990B (zh) * | 2009-09-21 | 2014-12-11 | Ferring Bv | 催產素受體促進劑 |
| AU2010302945B2 (en) * | 2009-10-01 | 2015-09-24 | The University Of Sydney | Therapy and prevention of problem drinking |
| WO2012016229A2 (en) | 2010-07-30 | 2012-02-02 | The Regents Of The University Of California | Oxytocin treatment to improve memory and modify blood glucose |
-
2014
- 2014-06-06 CR CR20160562A patent/CR20160562A/es unknown
-
2015
- 2015-06-03 EA EA201692488A patent/EA030296B1/ru not_active IP Right Cessation
- 2015-06-03 CN CN201580028538.6A patent/CN106459156A/zh active Pending
- 2015-06-03 WO PCT/EP2015/062314 patent/WO2015185584A1/en not_active Ceased
- 2015-06-03 KR KR1020167036061A patent/KR20170004014A/ko not_active Ceased
- 2015-06-03 MX MX2016015877A patent/MX2016015877A/es unknown
- 2015-06-03 JP JP2016571215A patent/JP6535688B2/ja not_active Expired - Fee Related
- 2015-06-03 CA CA2950493A patent/CA2950493A1/en not_active Abandoned
- 2015-06-03 PE PE2016002273A patent/PE20170427A1/es unknown
- 2015-06-03 EP EP15725069.7A patent/EP3152225B1/en not_active Not-in-force
- 2015-06-03 AU AU2015270564A patent/AU2015270564A1/en not_active Abandoned
- 2015-06-03 SG SG11201610221WA patent/SG11201610221WA/en unknown
-
2016
- 2016-10-30 IL IL248625A patent/IL248625A0/en unknown
- 2016-11-11 PH PH12016502251A patent/PH12016502251A1/en unknown
- 2016-11-29 CL CL2016003076A patent/CL2016003076A1/es unknown
- 2016-12-05 US US15/368,902 patent/US20170081368A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CL2016003076A1 (es) | 2017-08-11 |
| AU2015270564A1 (en) | 2016-11-17 |
| EA030296B1 (ru) | 2018-07-31 |
| CN106459156A (zh) | 2017-02-22 |
| JP6535688B2 (ja) | 2019-06-26 |
| JP2017518313A (ja) | 2017-07-06 |
| IL248625A0 (en) | 2017-01-31 |
| CA2950493A1 (en) | 2015-12-10 |
| SG11201610221WA (en) | 2017-01-27 |
| WO2015185584A1 (en) | 2015-12-10 |
| US20170081368A1 (en) | 2017-03-23 |
| KR20170004014A (ko) | 2017-01-10 |
| PH12016502251A1 (en) | 2017-02-06 |
| EP3152225B1 (en) | 2018-11-14 |
| EA201692488A1 (ru) | 2017-05-31 |
| EP3152225A1 (en) | 2017-04-12 |
| CR20160562A (es) | 2017-01-06 |
| MX2016015877A (es) | 2017-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170427A1 (es) | Peptidos como agonistas de la oxitocina | |
| CL2016002348A1 (es) | Agonistas del receptor muscarínico | |
| UY32547A (es) | Piperidinas sustituidas como antagonistas de ccr3 | |
| PE20151060A1 (es) | Nuevos derivados de pirazina como agonistas del receptor cb2 | |
| ECSP18012103A (es) | Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r) | |
| NI201300043A (es) | Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano | |
| PE20160664A1 (es) | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina | |
| BR112015010649A2 (pt) | moduladores de gpr40 à base de pirrolidina | |
| AR095823A1 (es) | Compuesto de ciclopropanamina y uso del mismo | |
| CL2015002125A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
| CL2013003731A1 (es) | Compuestos derivados de carboxamida; composición farmacéutica que los comprende, y su uso como inhibidores de la fosfodiesterasa tipo 10a (pde10a) para el tratamiento de trastornos del snc, esquizofrenia, disfunción cognitiva relacionada con la esquizofrenia, trastornos bipolares, depresión, disfunción cognitiva, alteraciones cognitivas, trastornos del comportamiento asociados a la enfermedad de alzheimer, obesidad, enfermedad de huntington y ansiedad. | |
| PE20170438A1 (es) | Inhibidores espirociclicos de catepsina c | |
| UY35641A (es) | PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO) | |
| AR092555A1 (es) | 2-oxo-2,3-dihidro-indoles y su utilizacion para el tratamiento de trastornos del snc | |
| CO7280468A2 (es) | Antagonistas del receptor de 5-ht3 | |
| PE20161407A1 (es) | Piridina 5,6 disustituida -2-carboxamidas como agonistas del receptor canabinoide | |
| PE20151748A1 (es) | Inhibidores de bace1 | |
| MX2015011932A (es) | Moduladores de gpr120 de acido biciclo[2.2.2]. | |
| UY36257A (es) | “compuestos de imidazopiridazina”. | |
| PE20181446A1 (es) | Derivados de 5-etil-4-metil-pirazol-3-carboxamida con actividad como de taar | |
| MX2018014944A (es) | Tratamiento para la enfermedad de parkinson. | |
| AR103317A1 (es) | Moduladores de ciclopropil dihidrobenzofurano de receptores de melatonina | |
| ES2568909T3 (es) | Novedosos compuestos antagonistas del receptor de la neuroquinina 1 | |
| CR20160448A (es) | Nuevos derivados de piridina | |
| PE20160556A1 (es) | Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos |